EUVIMEDEUVIMED entdecken
Crossref

Exploring the therapeutic potential of gamma-glutamyl carboxylase in prostate cancer through integrated multi-omics analysis

Yuangao Xu, Jieyu Xiong, Yuanbo Xu, YiKun Wu, Yuanlin Wang, Hua Shi, Shuxiong Xu

Eurasian Journal of Medicine and Oncology · 22.01.2026 · 10 (5) · 025320342

DOI: 10.36922/ejmo025320342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 22.01.2026. Verfasst von Yuangao Xu und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Prostate cancer (PCa) treatment is often limited by heterogeneous therapeutic responses and the emergence of drug resistance, underscoring the urgent need to identify novel therapeutic targets.

Objective

This study aims to identify novel susceptibility genes associated with PCa risk by integrating genomic, transcriptomic, and proteomic data.

Methods

We performed a genome-wide summary-data-based Mendelian randomization (SMR) analysis leveraging cis-expression quantitative trait loci from multiple tissues and PCa phenotypes. We then applied Bayesian colocalization to confirm that the observed SMR signals reflected shared causal variants. To characterize gamma-glutamyl carboxylase (GGCX) expression in normal and malignant prostate tissues, we integrated bulk transcriptomic and proteomic data from The Cancer Genome Atlas, Gene Expression Omnibus, the International Cancer Genome Consortium, and the Human Protein Atlas. We further investigated the spatial distribution of GGCX within the tumor microenvironment using spatial transcriptomics and Spearman correlation analyses with key stromal and immune cell markers. Finally, we constructed a GGCX-centered gene set by combining weighted gene co-expression network analysis with a random forest model and performed GO and KEGG enrichment analyses to infer its potential biological functions and pathways.

Results

SMR identified 53 candidate genes associated with PCa phenotypes, including GGCX (p 0.95). GGCX expression was higher in PCa tissues than in normal prostate tissues (p

Zitieren

APA

Xu, Y., Xiong, J., Xu, Y., Wu, Y., Wang, Y., Shi, H., & Xu, S. (2026). Exploring the therapeutic potential of gamma-glutamyl carboxylase in prostate cancer through integrated multi-omics analysis. Eurasian Journal of Medicine and Oncology, 10(5), 025320342. https://doi.org/10.36922/ejmo025320342

Vancouver

Xu Y, Xiong J, Xu Y, Wu Y, Wang Y, Shi H, et al. Exploring the therapeutic potential of gamma-glutamyl carboxylase in prostate cancer through integrated multi-omics analysis. Eurasian Journal of Medicine and Oncology. 2026;10(5):025320342. doi:10.36922/ejmo025320342

BibTeX
@article{Xu2026,
  author = {Xu, Yuangao and Xiong, Jieyu and Xu, Yuanbo and Wu, YiKun and Wang, Yuanlin and Shi, Hua and Xu, Shuxiong},
  title = {Exploring the therapeutic potential of gamma-glutamyl carboxylase in prostate cancer through integrated multi-omics analysis},
  journal = {Eurasian Journal of Medicine and Oncology},
  year = {2026},
  volume = {10},
  number = {5},
  pages = {025320342},
  doi = {10.36922/ejmo025320342}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche